Send to

Choose Destination
J Pediatr. 2009 May;154(5):682-7. doi: 10.1016/j.jpeds.2008.11.036. Epub 2009 Jan 23.

Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents.

Collaborators (258)

Shapiro GG, DuHamel TR, Lasley MV, Chinn T, Hinatsu M, Furukawa CT, Altman LC, Virant FS, Williams PV, Kennedy MS, Becker JW, White G, Bierman CW, Crawford D, Eliassen H, Hammond B, Minotti DA, Reagan C, Sharpe M, Wighton TG, Weiss S, Fuhlbrigge A, Plunkett A, Madden N, Barrant P, Darcy C, Thompson K, Torda W, Tata M, Babigian S, Benson L, Caicedo J, Calder T, DeFilippo A, Dorsainvi C, Erickson J, Fulton P, Grace M, Gilbert J, Greineder D, Haynes S, Higham M, Jakubowski D, Kelleher S, Koslof J, Mandel D, Martin P, Martinez A, McAuliffe J, Nakamoto E, Pacella P, Parks P, Sagarin J, Seligsohn K, Swords S, Syring M, Traylor J, Van Horn M, Wells C, Whitman A, MacLusky I, Reisman J, Levison H, Hall A, Chay J, Miki M, Sananes R, Benedet Y, Carpenter S, Collinson M, Finlayson-Kulchin J, Gore K, Holmes N, Klassen S, Quenneville J, Wasson C, Adkinson NF Jr, Eggleston P, Aylward EH, Huss K, Pulsifer M, Rand C, Bollers N, Bull D, Hamilton R, Hyatt K, Limb S, Pessaro M, Philips S, Wheeler B, Szefler S, Nelson HS, Bender B, Covar R, Liu A, Spahn J, Sundström D, Phillips M, White MP, Brelsford K, Bridges J, Ciacco J, Eltz M, Feeley J, Flynn M, Gleason M, Junk-Blanchard T, Hassell J, Hefner M, Hendrickson C, Hettleman D, Irvin CG, Jacobs J, Kamada A, Nimmagadda S, Sandoval K, Sheridan J, Washington T, Willcutt E, Carel K, Jain N, Leo H, Macomber B, Mjaanes C, Stewart L, Song B, Zeiger RS, Friedman N, Mellon MH, Schatz M, Harden K, Jenson EM, Panzlau S, Rodriguez E, Easton JG, Feinberg M, Galbreath LL, Gulczynski J, Hansen E, Jalowayski A, Lincoln A, Kaufman J, King S, Lopez B, Magiari-Ene M, Mostafa K, Moscona A, Nelle CA, Powers J, Sandoval K, Wilson NW, Kelly HW, Jacobs A, Spicher M, Raissy HH, Annett R, Archibeque T, Bashir N, Bereket HS, Braun M, Bush S, Clayton M, Colon-Semidey A, Devault S, Grad R, Hunt D, Larsson J, McClelland S, McWilliams B, Montoya E, Moreshead M, Murphy S, Ortega B, Weers D, Zayas J, Strunk RC, Bacharier L, Bloomberg GR, Corry JM, Rodgers D, Kertz L, Morgan V, Oliver-Welker T, Whit DK, Cherniack R, Tonascia J, Meinert C, Belt P, Collins K, Collison B, Colvin R, Dodge J, Donithan M, Harle J, Jackson R, Livingston H, Meinert J, Owens K, Smith M, Sternberg A, Van Natta M, Wild M, Wilson L, Wise R, Yates K, Taggart V, Eggers L, Kiley J, Zheng G, Albert P, Hurd S, Parker S, Randall P, Wu M, Eigen H, Cloutier M, Connett J, Cuttler L, Evans D, Kattan M, Menendez R, Simons FE, Davis CE, Leikin S, Cherniack R, Strunk R, Szefler S, Taggart V, Tonascia J, Meinert C, Cherniack R, Strunk R, Adkinson NF, Annett R, Bender B, Caesar M, DuHamel TR, Kelly HW, Levison H, Lincoln A, MacLusky I, McWilliams B, Meinert CL, Parker S, Reisman J, Rodgers D, Seligsohn K, Shapiro GG, Sharpe M, Sundström D, Szefler S, Taggart V, Tata M, Tonascia J, Weiss S, Wheeler B, Wise R, Zeiger R.

Author information

Department of Pediatrics, Washington University School of Medicine, St Louis Children's Hospital, St. Louis, MO 63110, USA.



To determine whether long-term, continuous use of inhaled anti-inflammatory medications affects asthma outcomes in children with mild to moderate asthma after use is discontinued.


Of the 1041 participants in the Childhood Asthma Management Program randomized clinical trial, 941 (90%) were followed to determine whether 4.3 years of twice-daily budesonide or nedocromil administration (each compared with placebo) affected subsequent asthma outcomes during a 4.8-year posttrial period in which treatment was managed by the participants' physicians.


The groups treated continuously during the trial with either budesonide or nedocromil did not differ from the group given placebo in terms of lung function, control of asthma, or psychological status at the end of 4.8 years of posttrial follow-up. However, the decreased mean height in the budesonide group relative to the placebo group at the end of the trial (1.1 cm; P = .005) remained statistically significant (0.9 cm; P = .01) after an additional 4.8 years and was more pronounced in girls (1.7 cm; P = .001) than in boys (0.3 cm; P = .49). Participants in all groups used inhaled corticosteroids during 30% of the posttrial period.


Clinically meaningful improvements in the control of asthma and in airway responsiveness achieved during continuous treatment with inhaled corticosteroids do not persist after continuous treatment is discontinued.

[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms


Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center